Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Trump Buys SpaceX Shares After Record IPO 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Ampol Profit Surges as Refining Margins Hit Record Highs 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Add as a preferred source on Google
STAMFORD, Conn., May 02, 2018 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Wednesday, May 9, 2018, at 4:30 p.m. ET to report first quarter 2018 financial results and provide a corporate update.
To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 1264618. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.
An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body's peripheral nervous system, as well as certain immune cells. In Phase 2 trials, KORSUVA injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) and is currently being investigated in Phase 3 trials in hemodialysis patients with CKD-aP. Additionally, CR845/difelikefalin has demonstrated efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available opioid pain therapeutics.
The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product, and its safety and efficacy have not been fully evaluated by any regulatory authority.
INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations
212-362-1200
[email protected]
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
[email protected]
